Matthew Lee

Mr. Matthew Lee

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2026 in Clinical Chemistry
Verified
Journal Article
Closed access
MLMatthew Lee
Matthew Lee
JSJeffrey SoRelle
Jeffrey SoRelle
AEArun Everest-Dass
Arun Everest-Dass
DGDavid Gerber
David Gerber
MIMitchell S von Itzstein
Mitchell S von Itzstein
Background: Immune checkpoint inhibitors (ICIs) have transformed oncology practice. However, treatment response remains heterogeneous, rendering predictive biomarkers critical for optimal patient care. The 3 established biomarkers, programmed death-ligand 1, tumor mutational burden (TMB), and microsatellite instability-high/deficient mismatch repair, are approved and clinically validated but are modest predictors of benefit. As a result, multiple novel predictive biomarkers remain under investigation. Content: This review highlights established and investigational predictive ICI efficacy biomarkers. For established biomarkers, we describe biology, assay modalities, approved companion diagnostics, landmark studies, and notable limitations. Due to the multisystem nature of antitumor immune effects, investigational biomarkers span multiple domains, including tumor genomic biomarkers (e.g., mutational signatures, TMB, neoantigen clonality), tumor microenvironment (e.g., tumor-infiltrating lymphocytes [TILs], tertiary lymphoid structures), systemic immune biomarkers (e.g., cytokines, autoantibodies, glycoproteins, peripheral blood mononuclear cells), and the microbiome (e.g., gastrointestinal microbial diversity, responder-enriched taxa). Summary: The established biomarkers PD-L1, TMB, and microsatellite instability-high/deficient mismatch repair inform ICI use in clinical practice but have important limitations. Multiple investigational biomarkers show promise in refining patient selection and optimizing therapy. Moving forward, increased assay harmonization, prospective validation, and standardized parameters may improve performance. Composite models integrating complementary signals across domains may further individualize treatment and lead to an era of personalized cancer immunotherapy.

11 March 2026 in Nicotine & Tobacco Research
Verified
Journal Article
Closed access
AWAlexander Wu
Alexander Wu
SSSumin Son
Sumin Son
MLMatthew Lee
Matthew Lee
SPSandi L Pruitt
Sandi L Pruitt
Chul AhnChul Ahn
Chul Ahn
DGDavid Gerber
David Gerber
Introduction: Although electronic cigarettes (e-cigarettes) have demonstrated efficacy for quitting combustible cigarette smoking, they also convey inherent risks. How the public views e-cigarettes and their potential harm may influence how e-cigarettes are used. We therefore evaluated perceptions of e-cigarettes over a recent 10-year period. Methods: Longitudinal data from a multiyear cross-sectional nationally representative survey, Health Information National Trends Survey, were analyzed to assess changes in perceptions of e-cigarettes’ harm relative to cigarettes and factors affecting perceptions among US adults from 2012 to 2022. We used interrupted time series regression analysis to determine possible associations with key public health events. Results: A total of 20 771 survey respondents were included in the analysis. From 2012 to 2022, the proportion perceiving e-cigarettes as more harmful than combustible cigarettes increased from 2.8% (95% CI, 1.8%–3.9%) to 30.4% (95% CI, 28.2%–32.7%). Likewise, perceptions of e-cigarettes as less harmful decreased from 50.7% (95% CI, 47.6%–53.9%) to 16.7% (95% CI, 14.9%–18.6%). Perceptions changed significantly following the national rollout of anti-vaping campaigns (p < .001) and the e-cigarette or vaping product use-associated lung injury outbreak (p < .001). Conclusions: Public perceptions of e-cigarettes have shifted markedly over the past decade, with increasing proportions of US adults viewing e-cigarettes as more harmful than combustible cigarettes. These changes appear closely linked to major public health events and campaigns. Understanding how such events influence perceptions is essential for guiding risk communication, public health policy, and future tobacco control strategies. Implications: How the public views electronic cigarettes (e-cigarettes) and their potential harm may influence how e-cigarettes are used. Although e-cigarettes convey risks, they have also demonstrated efficacy for quitting combustible cigarette smoking. We found that perceptions of e-cigarettes have shifted markedly over the past decade, with increasing proportions of US adults viewing e-cigarettes as more harmful than combustible cigarettes. How such perceptions influence smoking behavior represents an important consideration for risk communication, public health policy, and tobacco control strategies. Clear, evidenced-based messaging may reduce uptake of e-cigarette use, support harm-reduction efforts for current smokers, and promote trust in public health institutions.

10 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
MLMatthew Lee
Matthew Lee
QCQi Cai
Qi Cai
JWJue Wang
Jue Wang
Immune checkpoint inhibitors (ICIs) have transformed oncologic care and are increasingly used as adjuvant therapy to reduce the risk of recurrence. However, this shift has introduced immune-related adverse events (irAEs) to patients who may otherwise be clinically disease-free after definitive therapy. Sarcoidosis-like reaction (SLR) is an uncommon but important irAE characterized by non-necrotizing granulomatous inflammation. In the adjuvant setting, SLR is uniquely consequential because it can closely mimic recurrent malignancy on surveillance imaging and thereby prompt unnecessary diagnostic procedures, treatment interruption, or escalation of care. This review summarizes the current evidence on ICI-associated SLR with an emphasis on adjuvant immunotherapy, where practical guidance remains limited. We integrate evidence from clinical trials, real-world cohorts, and published case series to summarize the reported incidence of SLR, proposed immunologic mechanisms, clinical and radiographic presentation, pathology, differential diagnosis, and management. Particular attention is given to the problem of distinguishing SLR from recurrence, when tissue confirmation should be prioritized, and how management should be individualized according to clinical severity and organ involvement. Common radiographic features include bilateral mediastinal and hilar lymphadenopathy and pulmonary nodules, but tissue confirmation remains the diagnostic gold standard when feasible. Many cases are low grade and may be managed conservatively. Greater recognition of ICI-associated SLR is critical to avoid misdiagnosis and unnecessary escalation of care while preserving the therapeutic benefit of adjuvant immunotherapy.

10 October 2025 in Clinical Case Reports
Verified
Journal Article
Open access
MLMatthew Lee
Matthew Lee
APAnil K. Pillai
Anil K. Pillai
CFChristopher Fan
Christopher Fan
QCQi Cai
Qi Cai
KBKristi Baker
Kristi Baker
JWJue Wang
Jue Wang
Upper tract urothelial carcinoma (UTUC) is an uncommon and aggressive malignancy that often presents as an invasive disease. After receiving systemic therapy, stereotactic body radiation therapy (SBRT) offers a non‐surgical option for consolidative local tumor control by delivering radiation doses in limited fractions. While SBRT is generally well tolerated in the treatment of UTUC, there is a small but serious risk of radiation‐associated complications. We present a case of a 67‐year‐old male with metastatic UTUC of the renal pelvis treated with chemotherapy and immunotherapy. Due to persistent disease at the primary site, he underwent consolidative SBRT using a PULSAR (Personalized Ultra‐fractionated Stereotactic Adaptive Radiotherapy) approach to his left kidney mass. Weeks later, he developed a renocolic fistula that was complicated by sepsis. Despite a diverting colostomy and antibiotics, he re‐presented with hemorrhagic shock due to an aortocolonic fistula that required emergent endovascular aortic repair (EVAR). This case illustrates a rare but serious complication of consolidative SBRT in a patient with extensive retroperitoneal malignancy. Multidisciplinary planning and close surveillance are critical to ensuring the safe integration of SBRT in the management of metastatic UTUC.

15 September 2023 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
MLMatthew Lee
Matthew Lee
AVAndrew Vallejo
Andrew Vallejo
ZAZachary Anderson
Zachary Anderson
ARAlesandra R. Rau
Alesandra R. Rau
JWJason D. Wright
Jason D. Wright
KMKoji Matsuo
Koji Matsuo

1 January 2026 in Case Reports in Pulmonology
Verified
Journal Article
Open access
MLMatthew Lee
Matthew Lee
HAHussain Alkhafaji
Hussain Alkhafaji
MCMiguel Dario Cantu
Miguel Dario Cantu
KSKim Styrvoky
Kim Styrvoky
SWSteven Wu
Steven Wu
Lymphomatoid granulomatosis (LYG) is a rare, Epstein–Barr virus (EBV)–associated lymphoproliferative disorder characterized by angiocentric and angiodestructive infiltrates that most commonly involve the lungs. We report a case of a 38‐year‐old female with a history of latent tuberculosis who presented with a 3‐day history of fever, productive cough, bilateral lower extremity edema, and painless lower extremity skin lesions. Initial imaging revealed bilateral pulmonary nodules, and an extensive infectious workup was unrevealing. To obtain diagnostic tissue from peripheral lesions, she underwent robotic‐assisted bronchoscopy with targeted transbronchial biopsy. Histopathologic analysis revealed angiocentric and angiodestructive infiltrates with EBV positivity in CD20‐positive B cells, consistent with Grade 3 LYG. She was treated with dose‐adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA‐EPOCH‐R) chemotherapy, with initial radiographic response. However, she later developed refractory LYG complicated by hemophagocytic lymphohistiocytosis (HLH) and died of progressive disease. Robotic‐assisted bronchoscopy enabled safe, targeted sampling of peripheral pulmonary nodules, avoiding more invasive surgical biopsy.